Tag Archive for: cancer immunotherapy

Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer

/in

Pioneering cancer immunology company Asgard strengthens leadership team as it progresses its lead asset AT-108 towards clinical trials Shane brings over two decades of expertise in immunology-driven drug discovery with a specialized focus on novel modalities AT-108 is a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses Lund, Sweden, […]

Read more

Asgard Therapeutics’ study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108

/in

Study of Asgard’s new cancer immunotherapy modality demonstrates potent anti-tumor effects by turning tumor cells against themselves New data “paves the way for first-in-human trials” of lead program AT-108, which is undergoing CMC development for GMP manufacturing AT-108 is an off-the-shelf gene therapy that induces an immune response tailored against each unique patient’s cancer Lund, […]

Read more